Cara Therapeutics, Inc. (0HTC.L)
USD 0.25
(-1.15%)
USD 0.25
(-1.15%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 68.75 Million USD | 193.12% |
| 2022 | 23.45 Million USD | 20.09% |
| 2021 | 19.53 Million USD | -11.83% |
| 2020 | 22.15 Million USD | -52.09% |
| 2019 | 46.24 Million USD | -19.14% |
| 2018 | 57.19 Million USD | 459.4% |
| 2017 | 10.22 Million USD | -21.97% |
| 2016 | 13.1 Million USD | 123.87% |
| 2015 | 5.85 Million USD | 37.01% |
| 2014 | 4.27 Million USD | -35.0% |
| 2013 | 6.57 Million USD | 112.14% |
| 2012 | 3.09 Million USD | -32.37% |
| 2011 | 4.58 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 60.29 Million USD | -12.31% |
| 2024 Q2 | 60.89 Million USD | 1.0% |
| 2023 FY | 68.75 Million USD | 193.12% |
| 2023 Q2 | 25.45 Million USD | 52.64% |
| 2023 Q1 | 16.67 Million USD | -28.9% |
| 2023 Q3 | 29.69 Million USD | 16.65% |
| 2023 Q4 | 68.75 Million USD | 131.54% |
| 2022 Q1 | 19.75 Million USD | 1.11% |
| 2022 FY | 23.45 Million USD | 20.09% |
| 2022 Q4 | 23.45 Million USD | -18.23% |
| 2022 Q3 | 28.68 Million USD | 29.52% |
| 2022 Q2 | 22.15 Million USD | 12.15% |
| 2021 Q1 | 19.76 Million USD | -10.77% |
| 2021 Q3 | 17.9 Million USD | -0.48% |
| 2021 Q4 | 19.53 Million USD | 9.12% |
| 2021 FY | 19.53 Million USD | -11.83% |
| 2021 Q2 | 17.98 Million USD | -9.01% |
| 2020 Q1 | 35.69 Million USD | -22.81% |
| 2020 FY | 22.15 Million USD | -52.09% |
| 2020 Q3 | 19.28 Million USD | -30.33% |
| 2020 Q4 | 22.15 Million USD | 14.86% |
| 2020 Q2 | 27.68 Million USD | -22.45% |
| 2019 Q4 | 46.24 Million USD | -10.9% |
| 2019 FY | 46.24 Million USD | -19.14% |
| 2019 Q1 | 56.06 Million USD | -1.97% |
| 2019 Q2 | 50.09 Million USD | -10.65% |
| 2019 Q3 | 51.9 Million USD | 3.6% |
| 2018 Q2 | 66.81 Million USD | 683.13% |
| 2018 FY | 57.19 Million USD | 459.4% |
| 2018 Q4 | 57.19 Million USD | -9.47% |
| 2018 Q1 | 8.53 Million USD | -16.55% |
| 2018 Q3 | 63.17 Million USD | -5.45% |
| 2017 Q1 | 14.03 Million USD | 7.07% |
| 2017 Q3 | 8.97 Million USD | 2.51% |
| 2017 Q4 | 10.22 Million USD | 13.94% |
| 2017 FY | 10.22 Million USD | -21.97% |
| 2017 Q2 | 8.75 Million USD | -37.61% |
| 2016 Q2 | 9.45 Million USD | 33.46% |
| 2016 FY | 13.1 Million USD | 123.87% |
| 2016 Q1 | 7.08 Million USD | 21.07% |
| 2016 Q4 | 13.1 Million USD | 56.92% |
| 2016 Q3 | 8.35 Million USD | -11.71% |
| 2015 Q1 | 4.23 Million USD | -0.98% |
| 2015 FY | 5.85 Million USD | 37.01% |
| 2015 Q4 | 5.85 Million USD | 45.09% |
| 2015 Q3 | 4.03 Million USD | 1.59% |
| 2015 Q2 | 3.97 Million USD | -6.12% |
| 2014 Q3 | 7.03 Million USD | 6.2% |
| 2014 Q1 | 6.82 Million USD | 3.88% |
| 2014 FY | 4.27 Million USD | -35.0% |
| 2014 Q4 | 4.27 Million USD | -39.29% |
| 2014 Q2 | 6.62 Million USD | -2.94% |
| 2013 Q4 | 6.57 Million USD | -22.47% |
| 2013 Q2 | 8.79 Million USD | 0.0% |
| 2013 Q1 | - USD | -100.0% |
| 2013 FY | 6.57 Million USD | 112.14% |
| 2013 Q3 | 8.47 Million USD | -3.63% |
| 2012 FY | 3.09 Million USD | -32.37% |
| 2012 Q4 | 3.09 Million USD | 0.0% |
| 2011 FY | 4.58 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | 54.178% |
| Dynavax Technologies Corporation | 375.02 Million USD | 81.665% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 85.894% |
| Perrigo Company plc | 6.04 Billion USD | 98.862% |
| Illumina, Inc. | 4.36 Billion USD | 98.425% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.867% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 64.872% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.9% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.666% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 73.191% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.033% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -84.38% |
| Waters Corporation | 3.47 Billion USD | 98.022% |
| Biogen Inc. | 12.04 Billion USD | 99.429% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 16.588% |
| Evolus, Inc. | 209.68 Million USD | 67.209% |
| Adicet Bio, Inc. | 37.12 Million USD | -85.234% |
| bluebird bio, Inc. | 424.62 Million USD | 83.807% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 89.594% |
| FibroGen, Inc. | 585.72 Million USD | 88.261% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 98.602% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -95.465% |
| Homology Medicines, Inc. | 118.53 Million USD | 41.992% |
| Geron Corporation | 146.12 Million USD | 52.946% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 98.302% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 88.869% |
| Myriad Genetics, Inc. | 312.9 Million USD | 78.025% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -242.579% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 72.585% |
| Zoetis Inc. | 9.29 Billion USD | 99.26% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -39.822% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 98.039% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 96.362% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 98.665% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -41.932% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 97.359% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 74.027% |
| Verastem, Inc. | 71.18 Million USD | 3.408% |
| Nektar Therapeutics | 267.04 Million USD | 74.252% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 82.692% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -70.932% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 97.141% |
| OPKO Health, Inc. | 622.47 Million USD | 88.954% |
| Exelixis, Inc. | 678.44 Million USD | 89.865% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 93.255% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 40.112% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -448.58% |
| uniQure N.V. | 624.01 Million USD | 88.981% |
| Imunon, Inc. | 8.53 Million USD | -706.044% |
| Blueprint Medicines Corporation | 918.64 Million USD | 92.515% |
| Insmed Incorporated | 1.66 Billion USD | 95.862% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 95.831% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 45.472% |
| TG Therapeutics, Inc. | 169.08 Million USD | 59.335% |
| Incyte Corporation | 1.59 Billion USD | 95.682% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 94.2% |